PREVENT Cancer Preclinical Drug Development Program

The PREVENT Cancer Preclinical Drug Development Program is a Master Indefinite Delivery/Indefinite Quantity (IDIQ) contract administered by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH). The contract vehicle focuses on preclinical development of cancer prevention therapies, specifically supporting the manufacturing of vaccines and biologicals using current Good Manufacturing Practices (cGMP). The vehicle enables NCI to expedite translational research by providing a flexible procurement mechanism for advanced biomedical research and development related to potential cancer prevention interventions.

The task orders under this IDIQ demonstrate a focus on specialized vaccine and biologics development, with recent awards ranging from $1.3 million to $4.1 million. Prime contractors have included Advanced Bioscience Laboratories, Inc. and Kindred Biosciences, Inc., both specialized in gene therapies, vaccines, and immunotherapies. The delivery orders typically involve manufacturing specific vaccine candidates, such as an HPV-related vaccine and a vaccine targeting frame-shift mutations in tumors with microsatellite instability. These task orders are structured as cost-plus-fixed-fee contracts, have performance periods ranging from one to several years, and are primarily performed at contractor facilities in locations like Burlingame, California. No set-aside designations were identified in the reviewed task orders, indicating open competition among qualified contractors.